Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8892
−$0.0385 · -4.15%
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Latest quote
$0.8892
−$0.0385 · -4.15%
After-hours
$0.91
+$0.0208 · +2.34%
Sep 16, 7:49 PM ET
Regular session · ET · Market data may be delayed.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Day range
Current $0.8892
52-week range
Current $0.8892
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
37
Expensive
Sentiment
31
Bearish
Risk
63
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Day range
Current $0.8892
52-week range
Current $0.8892
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.55M USD | — | 1M USD | 5M USD | 15M USD |
| Cost of goods sold | 114K USD | — | — | — | — |
| Gross profit | 1.43M USD | — | 1M USD | 5M USD | 15M USD |
| Research and development | 18.11M USD | 14.36M USD | 31.05M USD | 39.83M USD | 38.67M USD |
| Selling, general, and administrative | 17.27M USD | 27.75M USD | 31.05M USD | 24.81M USD | 19.4M USD |
| Operating expenses | 63.92M USD | 42.1M USD | 62.1M USD | 64.64M USD | 58.07M USD |
| Interest income | 2.92M USD | 4.16M USD | 3.97M USD | 1.25M USD | 220K USD |
| Interest expense | 3.84M USD | −3.58M USD | 2.55M USD | — | — |
| Depreciation and amortization | 114K USD | 105K USD | 92K USD | 89K USD | 93K USD |
| Operating income | −62.49M USD | −42.1M USD | −61.1M USD | −59.64M USD | −43.07M USD |
| Net income | −63.06M USD | −41.52M USD | −59.69M USD | −58.39M USD | −42.85M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.50
406.07% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
